Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Hong Kong · Delayed Price · Currency is HKD

57.30

-1.70 (-2.88%)

Apr 17, 2026, 2:32 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Elimination of Inter-Segment	-53.44M		-	-32.93M	-21.10M	-19.12M
Antibody Development	332.35M		175.87M	126.89M	88.61M	41.09M
Antibody Development Growth	-		38.60%	43.20%	115.62%	-
Gene Editing	72.02M		74.33M	61.08M	51.15M	68.89M
Gene Editing Growth	-		21.69%	19.41%	-25.75%	-
Pre-Clinical Pharmacology and Efficacy Evaluation	352.20M		193.40M	176.07M	105.61M	75.38M
Pre-Clinical Pharmacology and Efficacy Evaluation Growth	-		9.84%	66.72%	40.11%	-
Animal Models Selling	675.62M		272.81M	202.26M	128.66M	85.06M
Animal Models Selling Growth	-		34.88%	57.20%	51.25%	-
Others	51.50K		516.00K	522.00K	1.64M	2.24M
Others Growth	-		-1.15%	-68.19%	-26.71%	-
Total	1.38B		716.91M	533.88M	354.56M	253.54M
Total Growth	-		34.28%	50.58%	39.84%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
China	438.38M		308.61M	287.74M	219.00M	162.71M
China Growth	-		7.25%	31.39%	34.60%	-
Overseas	940.38M		-	-	-	-
The United States of America (USA)	-		301.17M	178.99M	102.12M	62.89M
The United States of America (USA) Growth	-		68.26%	75.28%	62.37%	-
Others	-		107.13M	67.15M	33.44M	12.34M
Others Growth	-		59.54%	100.81%	171.03%	-
Korea	-		-	-	-	15.61M
Total	1.38B		716.91M	533.88M	354.56M	253.54M
Total Growth	-		34.28%	50.58%	39.84%	-

Source: S&P Global Market Intelligence.